GlassScriptPhysician profile
Brian S Banks
NPI 1780067645
$46,620.04
in general payments reported to CMS, 2019-2025
21 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $885 · 2023: $2,271 · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $15K · Food and Beverage: $5,196 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,857.80 |
| Travel and Lodging | $14,959.24 |
| Food and Beverage | $5,195.83 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $43,453.23 | 2023-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,152.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $327.00 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $218.40 | 2021-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $217.12 | 2021-2025 | Trintellix |
| Lundbeck LLC | $213.96 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.66 | 2022-2025 | Caplyta |
| Corium, LLC | $149.30 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $132.74 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $109.25 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $98.61 | 2022-2023 | Jornay Pm |
| Tris Pharma INC | $80.10 | 2021-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $72.80 | 2021-2022 | |
| Tempus Ai, INC | $44.33 | 2024 | |
| Neurocrine Biosciences, INC. | $38.37 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.07 | 2025 | Cobenfy |
| Alkermes, INC. | $28.68 | 2023 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $20.27 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $17.88 | 2024 | Relexxii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.42 | 2022 | |
| Allergan, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Banks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.